Last checked at 6 Dec 2017 07:00
Nuformix plc
("Nuformix" or "the Company")
Grant of Warrants at 6p per share
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces that Warrants over new ordinary shares have been granted to Beaufort Securities Limited, and have vested in accordance with the terms agreed with its recent appointment as the Company's broker:
Warrants over no. of shares | Exercise price per share | Lapse date |
1,000,000 | 6 pence | 20 November 2020 |
Follow Nuformix on Vox Markets: follow at www.voxmarkets.co.uk/company/NFX
and www.nuformix.com
Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.
ENDS
Enquiries:
Nuformix plc Dan Gooding, Chief Executive Officer | +44 (0)1223 423667
|
Beaufort Securities Limited (Joint Broker) Jon Belliss | +44 (0)20 7382 8300
|
Gable Communications Ltd John Bick / Justine James | +44 (0)20 7193 7463
|
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2008 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.